Evidence map›Paper›PMID 33732239›Full record

ArticleFrontiers in immunology2021

Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.

Arthur Dopler, Selina Stibitzky, Rachel Hevey, Marco Mannes, Mara Guariento, Britta Höchsmann, Hubert Schrezenmeier, Daniel Ricklin, Christoph Q Schmidt

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The human factor H protein family - an update.Frontiers in immunology · 2024
    Review
  6. Article
  7. Article
  8. Frontiers in immunology · 2022
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Arthur DoplerInstitute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany.
Selina StibitzkyInstitute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany.
Rachel HeveyDepartment of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Marco MannesInstitute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany.
Mara GuarientoInstitute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany.
Britta HöchsmannInstitute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Hubert SchrezenmeierInstitute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Daniel RicklinDepartment of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Christoph Q SchmidtInstitute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany.
Universität Ulm · DEUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To discriminate between self and non-self surfaces and facilitate immune surveillance, the complement system relies on the interplay between surface-directed activators and regulators. The dimeric modulator FHR-1 is hypothesized to competitively remove the complement regulator FH from surfaces that strongly fix opsonic C3b molecules-a process known as "deregulation." The C-terminal regions of FH and FHR-1 provide the basis of this competition. They contain binding sites for C3b and host surface markers and are identical except for two substitutions: S1191L and V1197A (i.e., FH "SV"; FHR-1 "LA"). Intriguingly, an FHR-1 variant featuring the "SV" combination of FH predisposes to atypical hemolytic uremic syndrome (aHUS). The functional impact of these mutations on complement (de)regulation, and their pathophysiological consequences, have largely remained elusive. We have addressed these questions using recombinantly expressed wildtype, mutated, and truncated versions of FHR-1 and FH. The "SV" to "LA" substitutions did not affect glycosaminoglycan recognition and had only a small effect on C3b binding. In contrast, the two amino acids substantially affected the binding of FH and FHR-1 to α2,3-linked sialic acids as host surfaces markers, with the S-to-L substitution causing an almost complete loss of recognition. Even with sialic acid-binding constructs, notable deregulation was only detected on host and not foreign cells. The aHUS-associated "SV" mutation converts FHR-1 into a sialic acid binder which, supported by its dimeric nature, enables excessive FH deregulation and, thus, complement activation on host surfaces. While we also observed inhibitory activities of FHR-1 on C3 and C5 convertases, the high concentrations required render the physiological impact uncertain. In conclusion, the SV-to-LA substitution in the C-terminal regions of FH and FHR-1 diminishes its sialic acid-binding ability and results in an FHR-1 molecule that only moderately deregulates FH. Such FH deregulation by FHR-1 only occurs on host/host-like surfaces that recruit FH. Conversion of FHR-1 into a sialic acid binder potentiates the deregulatory capacity of FHR-1 and thus explains the pathophysiology of the aHUS-associated FHR-1 "SV" variant.

Indexed as

Gene Expression RegulationAnimalsBlood ProteinsComplement C3Complement C3bComplement C3-C5 ConvertasesComplement Factor HEndothelial CellsErythrocytesHemolysisHumansMutationN-Acetylneuraminic AcidProtein BindingProtein Processing, Post-TranslationalRabbitsBlood ProteinsComplement C3Complement C3bComplement C3-C5 ConvertasesComplement Factor Hfactor H-related protein 1N-Acetylneuraminic Acidcomplement systemfactor H (FH)factor H related protein 1FH deregulationFHR-1sialic acid

Identifiers

PMID33732239
PMCPMC7959842
OpenAlexW3130014840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.